12/19/2016

Mannitol Injection

Products Affected - Description

- Mannitol injection, American Regent, 250 mg/mL, 50 mL vial, 25 count, NDC 00517-4050-25

Reason for the Shortage

- American Regent has mannitol injection on shortage due to manufacturing delays.

Available Products

- Osmitrol injection, Baxter, 200 mg/mL, 250 mL premixed bag, 36 count, NDC 00338-0357-02
- Osmitrol injection, Baxter, 200 mg/mL, 500 mL premixed bag, 24 count, NDC 00338-0357-03
- Osmitrol injection, Baxter, 50 mg/mL, 1000 mL premixed bag, 14 count, NDC 00338-0351-04
- Mannitol injection, BBraun, 200 mg/mL, 250 mL premixed bag, 1 count, NDC 00264-7578-20
- Mannitol injection, BBraun, 200 mg/mL, 500 mL premixed bag, 1 count, NDC 00264-7578-10
- Mannitol injection, Fresenius Kabi, 250 mg/mL, 50 mL vial, 25 count, NDC 63323-0024-25
- Mannitol injection, Pfizer, 200 mg/mL, 250 mL premixed bag, 24 count, NDC 00409-7715-02
- Mannitol injection, Pfizer, 200 mg/mL, 500 mL premixed bag, 12 count, NDC 00409-7715-03
- Mannitol injection, Pfizer, 250 mg/mL, 50 mL vial, 25 count, NDC 00409-4031-01

Estimated Resupply Dates

- American Regent has mannitol 250 mg/mL 50 mL vials on back order and the company cannot estimate a release date.
- All other marketed presentations are available.

Updated

Updated December 19, 2016 by Michelle Wheeler, PharmD, Drug Information Specialist. Created August 5, 2015 by Jane Chandramouli, PharmD, Drug Information Specialist. Copyright 2017, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.